



# Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study

Luis M. Ruilope<sup>1,2,3</sup>, Bertram Pitt<sup>4</sup>, Stefan D. Anker<sup>5</sup>, Peter Rossing<sup>6,7</sup>, Csaba P. Kovesdy<sup>8</sup>, Roberto Pecoits-Filho<sup>9,10</sup>, Pablo Pergola<sup>11</sup>, Amer Joseph<sup>12</sup>, Andrea Lage<sup>13</sup>, Nicole Mentenich<sup>14</sup>, Markus F. Scheerer<sup>15</sup> and George L. Bakris<sup>16</sup>; on behalf of the FIGARO-DKD Investigators

<sup>1</sup>Cardiorenal Translational Laboratory and Hypertension Unit, Institute of Research imas12, Madrid, Spain, <sup>2</sup>CIBER-CV, Hospital Universitario 12 de Octubre, Madrid, Spain, <sup>3</sup>Faculty of Sport Sciences, European University of Madrid, Madrid, Spain, <sup>4</sup>Department of Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA, <sup>5</sup>Department of Cardiology (CVK), and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany, <sup>6</sup>Steno Diabetes Center Copenhagen, Gentofte, Denmark, <sup>7</sup>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, <sup>8</sup>Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA, <sup>9</sup>Arbor Research Collaborative for Health, Ann Arbor, MI, USA, <sup>10</sup>School of Medicine, Pontificia Universidade Católica do Paraná, Curitiba, Brazil, <sup>11</sup>Renal Associates, PA, San Antonio, TX, USA, <sup>12</sup>Research and Development, Cardiology and Nephrology Clinical Development, Bayer AG, Berlin, Germany, <sup>13</sup>Cardiology and Nephrology Clinical Development, Bayer SA, São Paulo, Brazil, <sup>14</sup>Statistics and Data Insights, Bayer AG, Wuppertal, Germany, <sup>15</sup>Global Medical Affairs & Pharmacovigilance, Pharmaceuticals, Bayer AG, Berlin, Germany and <sup>16</sup>Department of Medicine, University of Chicago Medicine, Chicago, IL, USA

Correspondence to: Luis M. Ruilope; E-mail: [ruilope@icloud.com](mailto:ruilope@icloud.com); George L. Bakris; E-mail: [gbakris@gmail.com](mailto:gbakris@gmail.com)

## ABSTRACT

**Background.** In FIGARO-DKD, finerenone reduced the risk of cardiovascular events in patients with type 2 diabetes (T2D) and stage 1–4 chronic kidney disease (CKD). In FIDELIO-DKD, finerenone improved kidney and cardiovascular outcomes in patients with advanced CKD. This analysis further explores kidney outcomes in FIGARO-DKD.

**Methods.** FIGARO-DKD (NCT02545049) included patients with urine albumin-to-creatinine ratio (UACR) 30–<300 mg/g and estimated glomerular filtration rate (eGFR) 25–90 mL/min/1.73 m<sup>2</sup> or UACR 300–5000 mg/g and eGFR ≥60 mL/min/1.73 m<sup>2</sup>. Outcomes included two composite kidney endpoints, a composite of ≥40% decrease in eGFR from baseline sustained over ≥4 weeks, kidney failure or renal death, and a composite of ≥57% decrease in eGFR from baseline sustained over ≥4 weeks, kidney failure or renal death. Changes in albuminuria and eGFR slope were also analyzed. Kidney and CV outcomes were evaluated by baseline UACR.

**Results.** A lower incidence rate for the eGFR ≥40% kidney composite endpoint was observed with finerenone compared with placebo, but the between-group difference was not significant [hazard ratio (HR) = 0.87; 95% confidence interval (CI): 0.76–1.01; *P* = .069]. A greater treatment effect was observed on the eGFR ≥57% kidney composite endpoint (HR = 0.77; 95% CI: 0.60–0.99; *P* = 0.041) with a 36% relative risk reduction for end-stage kidney disease. A larger magnitude of effect on kidney outcomes was observed with finerenone versus placebo for patients with severely increased albuminuria than with moderately increased albuminuria. Improvements in UACR, eGFR slope and cardiovascular risk were evident in both subgroups with finerenone.

**Conclusions.** The present analyses suggest that finerenone protects against kidney disease progression and cardiovascular events in patients with T2D and early- or late-stage CKD.

**Keywords:** albuminuria, chronic kidney disease, finerenone, kidney outcomes, type 2 diabetes

# Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study

## Background

The aim was to evaluate the effects of finerenone on kidney outcomes in patients with CKD and T2D.

## Methods



**FIGARO-DKD trial (NCT02545049)**  
7437 patients with T2D and CKD



### Kidney composite outcomes:

Time to kidney failure, sustained  $\geq 40\%$ / $\geq 57\%$  decrease from baseline in eGFR over  $\geq 4$  weeks, or renal death




### CV composite outcome:

Time to CV death, non-fatal MI, non-fatal stroke, or hospitalization for HF

Acknowledgments: Funded by Bayer AG; FIDELIO-DKD

## Results



## Conclusion

**Finerenone protects against CV events and kidney disease progression in patients with T2D and early- or late-stage CKD.**



Ruilope et al. NDT (2022)  
@NDTSocial

## KEY LEARNING POINTS

### What is already known about this subject?

- Increased albuminuria is an independent marker of progression to kidney failure and adverse cardiovascular (CV) outcomes, and patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) remain at high risk despite best-recommended therapies.
- Finerenone is a novel, selective, nonsteroidal mineralocorticoid receptor antagonist that slowed CKD progression and improved CV outcomes versus placebo in patients with predominantly stage 3–4 CKD with severely increased albuminuria in the FIDELIO-DKD trial.
- In the FIGARO-DKD trial, finerenone reduced the risk of CV events in patients with stage 2–4 CKD and moderately increased albuminuria or stage 1–2 CKD with severely increased albuminuria. Although there was a trend favoring finerenone for the first kidney composite endpoint, this difference was not statistically significant.

### What this study adds?

- The purpose of this analysis was to further evaluate the effects of finerenone on kidney outcomes in patients with CKD and T2D in FIGARO-DKD.
- This exploratory analysis demonstrated that there are beneficial effects of finerenone on clinical kidney outcomes, including a 36% relative risk reduction of end-stage kidney disease compared with placebo.
- In FIGARO-DKD, despite showing greater treatment effects on kidney composite outcomes in patients with severely rather than moderately increased albuminuria, finerenone reduced the risk of CV events and markers of CKD progression in patients with both severely increased albuminuria and moderately increased albuminuria.

### What impact this may have on practice or policy?

- Finerenone offers an important treatment advance for patients with CKD and T2D with both moderately or severely increased albuminuria to protect against CV events and kidney disease progression.
- These findings emphasize the need for albuminuria screening in clinical practice for patients with T2D to enable earlier identification of CKD and initiation of appropriate treatment.

## INTRODUCTION

Diabetes is one of the main causes of kidney failure [1], and approximately 40% of patients with type 2 diabetes (T2D) globally are estimated to be affected by chronic kidney disease (CKD) [2]. Patients with CKD and T2D are also at increased risk of cardiovascular (CV) morbidity and mortality; compared with T2D alone, and comorbid CKD increases the risk of all-cause and CV mortality approximately threefold [3]. Albuminuria is an independent and robust prognostic marker of progression to kidney failure as well as CV disease. The risk of CV mortality and heart failure (HF) in patients with diabetes increases as albuminuria progresses beyond a urine albumin-to-creatinine ratio (UACR) of 10 mg/g and as estimated glomerular filtration rate (eGFR) falls below 75 mL/min/1.73 m<sup>2</sup> [4]. Standard-of-care in CKD and T2D includes control of blood glucose and blood pressure, and guidelines recommend treatment with a renin-angiotensin system (RAS) inhibitor and a sodium-glucose co-transporter-2 inhibitor (SGLT-2i) in most patients [5, 6]. However, patients with CKD and T2D remain at high risk of CV events and kidney disease progression despite best-recommended therapy, particularly for patients in whom albuminuria persists [7, 8]. Therefore, there remains a high therapeutic unmet need in these patients and an opportunity for drugs with mechanisms of action that extend beyond glomerular hemodynamics [7].

Finerenone is a novel, selective, nonsteroidal mineralocorticoid receptor antagonist (MRA) that slowed CKD progression and improved CV outcomes versus placebo in patients with predominantly stage 3–4 CKD with severely increased albuminuria in the Phase 3 FIDELIO-DKD trial [9]. FIGARO-DKD was a parallel study investigating the effect of finerenone in patients with earlier stages of CKD and included more patients with moderately increased albuminuria (UACR 30–<300 mg/g), a population under-represented in other studies in CKD. FIGARO-DKD showed a statistically significant benefit favoring finerenone versus placebo for the primary CV composite endpoint (time to CV death, nonfatal myocardial infarction, nonfatal stroke or hospitalization for HF) [10]. However, although there was a trend favoring finerenone for the first secondary kidney composite endpoint in the testing hierarchy (time to kidney failure, sustained  $\geq 40\%$  decrease in eGFR or renal death), this difference was not statistically significant [10].

The purpose of this exploratory analysis was to further evaluate the effects of finerenone on cardiorenal outcomes in patients with CKD and T2D beyond the results of the primary analysis. This investigation included prespecified subgroup analyses by baseline albuminuria to evaluate for treatment-effect heterogeneity.

## MATERIALS AND METHODS

### Study design and participants

The study design and eligibility criteria of FIGARO-DKD (NCT02545049), an international, multicenter, Phase 3, randomized, double-blind, placebo-controlled,

parallel group, event-driven trial, have been described in detail previously [11].

FIGARO-DKD enrolled patients aged  $\geq 18$  years with T2D and UACR 30 to <300 mg/g and eGFR 25–90 mL/min/1.73 m<sup>2</sup> (stage 2–4 CKD) or UACR 300–5000 mg/g and an eGFR  $\geq 60$  mL/min/1.73 m<sup>2</sup> (stage 1–2 CKD; Supplementary data, Fig. S1). In patients with UACR 30 to <300 mg/g, recruitment caps limited the proportion of patients with eGFR  $\geq 60$  mL/min/1.73 m<sup>2</sup> to approximately 10% of the total population, and those with no history of CV disease to approximately 40% of the total patient number. Eligible patients received a maximum tolerated labeled dose of a RAS inhibitor therapy and had serum potassium  $\leq 4.8$  mmol/L at screening. Key exclusion criteria included known significant nondiabetic causes of kidney disease, symptomatic HF with reduced ejection fraction and receipt of dialysis or a kidney transplant.

### Procedures and outcomes

The trial procedures and outcomes have been described in detail previously [10, 11]. Following run-in and adjustment of background medical therapies, eligible patients were randomly assigned (1:1) to receive finerenone or placebo (10 or 20 mg once daily). Following randomization, trial visits were conducted at months 1 and 4, then every 4 months until study completion. Treatment was withheld if serum potassium concentrations exceeded 5.5 mmol/L and restarted when serum potassium levels decreased to  $\leq 5.0$  mmol/L.

Kidney outcomes of interest for this analysis included an eGFR  $\geq 40\%$  kidney composite endpoint of time to kidney failure [defined as end-stage kidney disease (ESKD; the initiation of long-term dialysis for  $\geq 90$  days, or kidney transplantation) or an eGFR  $< 15$  mL/min/1.73 m<sup>2</sup> sustained for  $\geq 4$  weeks], a sustained  $\geq 40\%$  decrease in eGFR from baseline for  $\geq 4$  weeks, or renal death; a similar eGFR  $\geq 57\%$  kidney composite considered a sustained  $\geq 57\%$  decrease in eGFR from baseline for  $\geq 4$  weeks. A CV composite endpoint of time to CV death, nonfatal myocardial infarction, nonfatal stroke or hospitalization for HF was also analyzed. All potential endpoints were prospectively adjudicated by an independent clinical event committee blinded to treatment assignment.

Efficacy and safety outcomes were also analyzed by UACR subgroups at baseline. For the UACR subgroups, patients were defined as having either moderately increased albuminuria (UACR: 30 to <300 mg/g) or severely increased albuminuria (UACR: 300 to 5000 mg/g). A small subgroup of patients had UACR  $< 30$  mg/g at baseline and were excluded from subgroup analyses because of the limited sample size.

Albuminuria regression was defined as a change from severely increased to moderately increased albuminuria, or moderately increased albuminuria to normal albuminuria, accompanied by a UACR decrease from baseline of  $\geq 30\%$ . Albuminuria progression for patients with moderately increased albuminuria at baseline was defined as a change to severely increased albuminuria, accompanied by a UACR increase from baseline of  $\geq 30\%$ .

## Statistical analysis

Efficacy analyses were performed in the full analysis set (i.e. all randomized patients without critical Good Clinical Practice violations). Safety analyses were performed in the safety analysis set, consisting of all full analysis set patients who took  $\geq 1$  dose of study drug. A stratified log-rank test was used to analyze the superiority of finerenone versus placebo in time-to-event analyses. Treatment effects of time-to-event outcomes were expressed as hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) from a stratified Cox proportional hazards model. Events were reported from randomization up to the end-of-study visit. Patients without an event were censored at the date of their last contact, with complete information on all components of their respective outcomes.

All eGFR and UACR measurements from a central laboratory were considered for efficacy analyses, irrespective of discontinuation of study treatment but excluding values after the onset of ESKD. The ratio of UACR from baseline to month 4 and chronic eGFR slope (annualized change from month 4 to premature discontinuation or end-of-study visit) were analyzed with an analysis of covariance (ANCOVA) model with covariates of treatment group, stratification factors and baseline value. Treatment differences in UACR and eGFR over the course of the trial were analyzed with a mixed model using separate unstructured covariance patterns for each treatment group and adjusted for stratification factors, baseline value, time and interaction of time with treatment and baseline value, respectively. Additional details on the efficacy and safety analyses have been published previously [10].

## RESULTS

### Patients

Overall, 7437 patients were randomized in FIGARO-DKD [10]. Following the prospective exclusion of 85 patients from all analyses due to critical violations of Good Clinical Practice, 7352 were included in this analysis. The trial concluded after a median follow-up of 3.4 years, with 7334 (99.8%) patients completing the study [10]. At baseline, 3414 (46.4%) had moderately increased albuminuria (UACR: 30 to  $< 300$  mg/g), and 3729 (50.7%) had severely increased albuminuria (UACR  $\geq 300$  mg/g); 207 (2.8%) patients had normal albuminuria (UACR  $< 30$  mg/g) and for two ( $< 0.1\%$ ) patients no UACR value was available.

### Baseline characteristics in patients according to urine albumin-to-creatinine ratio status at baseline

At baseline, mean eGFR levels reflected the trial inclusion criteria. Patients with moderately increased albuminuria had a lower mean eGFR compared with patients with severely increased albuminuria (55.7 versus 79.6 mL/min/1.73 m<sup>2</sup>), and the proportions of patients with baseline eGFR  $< 60$  mL/min/1.73 m<sup>2</sup> were 65.3% and 11.7%, respectively (Supplementary data, Fig. S1 and Table 1).

Noteworthy differences in baseline characteristics between the two subgroups were likely related to the differences in

mean eGFR and the recruitment cap for history of CV disease. Patients with moderately increased albuminuria were older, had lower blood pressure, longer mean duration of diabetes and were more likely to report a history of CV disease (Table 1). Patients with moderately increased albuminuria were also less likely to be current smokers. Medication use at baseline was broadly similar in both groups, although patients with severely increased albuminuria reported lower use of statins, diuretics and  $\beta$ -blockers, and higher use of metformin and SGLT-2is at baseline (Table 1).

### Effects of finerenone on kidney outcomes in the overall population

As previously reported, there was a 13% relative risk reduction for the eGFR  $\geq 40\%$  kidney composite endpoint in the overall population; however, this was not statistically significant (HR: 0.87; 95% CI: 0.76–1.01;  $P = .069$ ) [10]. A sustained  $\geq 40\%$  decrease in eGFR from baseline was reported in 338 patients treated with finerenone and 385 patients treated with placebo (HR: 0.87; 95% CI: 0.75–1.00) (Fig. 1A). The risk of the eGFR  $\geq 57\%$  kidney composite endpoint was reduced with finerenone compared with placebo [108 (2.9%) versus 139 (3.8%) patients; HR: 0.77; 95% CI: 0.60–0.99;  $P = .041$ ]. In the finerenone group, 90 (2.4%) patients experienced a sustained  $\geq 57\%$  decrease in eGFR from baseline compared with 116 (3.2%) in the placebo group (HR: 0.76; 95% CI: 0.58–1.00;  $P = .053$ ) (Fig. 1B). There was a 36% relative risk reduction in ESKD with finerenone versus placebo, occurring in 32 (0.9%) patients treated with finerenone, compared with 49 (1.3%) patients treated with placebo (HR: 0.64; 95% CI: 0.41–0.995;  $P = .046$ ; Fig. 1C). Based on an absolute between-group difference of 0.6% (95% CI: 0–1.1) after 42 months, the number of patients who needed to be treated with finerenone to prevent one ESKD event was 175. The cumulative incidences for kidney failure and sustained decrease in eGFR to  $< 15$  mL/min/1.73 m<sup>2</sup> are shown in the Supplementary data, Fig. S2. Incidence of the eGFR  $\geq 57\%$  kidney composite endpoint by key subgroups is shown in the Supplementary data, Fig. S3. The treatment effect of finerenone appeared consistent in patients with or without a history of CV disease ( $P_{\text{interaction}} = 0.37$ ), by baseline glycated hemoglobin ( $P_{\text{interaction}} = 0.56$  for  $\leq 7.5\%$  versus  $> 7.5\%$ ) and by baseline systolic blood pressure ( $P_{\text{interaction}} = 0.14$  for above versus below median).

Finerenone reduced UACR compared with placebo, an effect that was maintained throughout the trial (Fig. 2A). A 32% greater reduction in the ratio of UACR from baseline to month 4 was seen with finerenone versus placebo (ratio of least-squares mean change from baseline 0.68; 95% CI: 0.65–0.70;  $P < .0001$ ) [10]. Overall, patients treated with finerenone had a significantly shorter time to albuminuria regression (from severely increased to moderately increased albuminuria, or from moderately increased to normal albuminuria, each accompanied by a UACR reduction of  $\geq 30\%$  from baseline) over time than placebo recipients (HR: 1.82; 95% CI: 1.69–1.96;  $P < .0001$ ; Fig. 2B).

In the overall population, placebo-corrected change in eGFR from baseline to month 4 with finerenone was

**Table 1. Baseline characteristics by albuminuria at baseline**

Characteristic	UACR at baseline	
	Moderately increased albuminuria (UACR: 30 to <300 mg/g) (baseline eGFR IQR 42–67 mL/min/1.73 m <sup>2</sup> ) (n = 3414)	Severely increased albuminuria (UACR ≥300 mg/g) (baseline eGFR IQR 68–92 mL/min/1.73 m <sup>2</sup> ) (n = 3729)
Age, years, mean ± SD	67.7 ± 8.6	60.6 ± 9.7
Sex, n (%)		
Male	2430 (71.2)	2548 (68.3)
Female	984 (28.8)	1181 (31.7)
Race, n (%)		
White	2532 (74.2)	2591 (69.5)
Black/African	128 (3.7)	125 (3.4)
Asian	633 (18.5)	783 (21.0)
Other <sup>b</sup>	121 (3.5)	230 (6.2)
SBP, mmHg, mean ± SD	134.6 ± 14.4	137.1 ± 13.5
DBP, mmHg, mean ± SD	74.8 ± 9.7	78.7 ± 9.0
BMI, kg/m <sup>2</sup> , mean ± SD	31.2 ± 5.9	31.6 ± 6.1
Duration of diabetes, years, mean ± SD	15.5 ± 9.0	13.5 ± 7.9
HbA1c, %, mean ± SD	7.6 ± 1.3	7.9 ± 1.4
Serum potassium, mEq/L, mean ± SD	4.35 ± 0.42	4.31 ± 0.43
eGFR, mL/min/1.73 m <sup>2</sup> , mean ± SD	55.7 ± 18.8	79.6 ± 17.3
eGFR, mL/min/1.73 m <sup>2</sup> , n (%)		
≥60	1183 (34.7)	3292 (88.3)
45 to <60	1126 (33.0)	336 (9.0)
25 to <45	1081 (31.7)	98 (2.6)
<25	24 (0.7)	2 (<0.1)
UACR, mg/g, median (IQR)	113 (65–187)	730 (459–1304)
History of CV disease, n (%)	1837 (53.8)	1367 (36.7)
Current smoker, n (%)	431 (12.6)	837 (22.4)
Medication use at baseline, n (%)		
RAS inhibitors	3409 (99.9)	3725 (99.9)
Beta blockers	1802 (52.8)	1618 (43.4)
Diuretics	1825 (53.5)	1562 (41.9)
Statins	2561 (75.0)	2465 (66.1)
Potassium supplements	120 (3.5)	90 (2.4)
Potassium-lowering agents	28 (0.8)	18 (0.5)
Glucose-lowering therapies	3318 (97.2)	3676 (98.6)
Insulin	1791 (52.2)	2102 (56.4)
Metformin	2104 (61.6)	2835 (76.0)
SGLT-2i	244 (7.1)	358 (9.6)
GLP-1RA	263 (7.7)	272 (7.3)

<sup>a</sup>207 patients with UACR <30 mg/g and 2 patients with missing UACR were excluded from this analysis.

<sup>b</sup>Other = Native American, Native Hawaiian Islander, not reported and multiple.

BMI, body mass index; CV, cardiovascular; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated hemoglobin; IQR, interquartile range; RAS, renin-angiotensin system; SBP, systolic blood pressure; SD, standard deviation; SGLT-2i, sodium-glucose co-transporter-2 inhibitor; UACR, urine albumin-to-creatinine ratio.




–2.24 mL/min/1.73 m<sup>2</sup> (least-squares mean difference –3.46 versus –1.22 mL/min/1.73 m<sup>2</sup> for finerenone and placebo, respectively; *P* < .0001; Supplementary data, Fig. S4). However, placebo-corrected change in chronic eGFR slope from month 4 to permanent discontinuation or the end of study with finerenone was 1.13 mL/min/1.73 m<sup>2</sup> (least-squares mean difference –2.37 versus –3.50 mL/min/1.73 m<sup>2</sup> for finerenone and placebo, respectively; *P* < .0001).

**Effect of finerenone on kidney and cardiovascular outcomes in patients according to urine albumin-to-creatinine ratio status at baseline**

**Kidney outcomes by urine albumin-to-creatinine ratio at baseline.** A greater improvement in the incidence rate of

the eGFR ≥40% kidney composite endpoint was observed with finerenone versus placebo in patients with severely increased albuminuria at baseline than in those with moderately increased albuminuria at baseline (HR: 0.74; 95% CI: 0.62–0.90 and HR: 1.16; 95% CI: 0.91–1.47, respectively; *P*<sub>interaction</sub> = .02) (Fig. 3). Similarly, the treatment effect of finerenone versus placebo for the eGFR ≥57% kidney composite endpoint appeared more pronounced in patients with severely increased albuminuria at baseline than in those with moderately increased albuminuria at baseline (HR: 0.69; 95% CI: 0.51–0.93 and HR: 1.05; 95% CI: 0.65–1.71, respectively; *P*<sub>interaction</sub> = .37) (Fig. 3). This trend was consistent across the components of the composite kidney endpoints (Supplementary data, Fig. S5).

Evaluation of the chronic eGFR slope by UACR subgroups showed a slower decline among patients in the placebo


**A Sustained  $\geq 40\%$  decrease in eGFR from baseline****B Sustained  $\geq 57\%$  decrease in eGFR from baseline****C End-stage kidney disease**

**FIGURE 1:** Kidney outcomes in the overall population. CI, confidence interval; eGFR, estimated glomerular filtration rate.

group with moderately increased albuminuria compared with severely increased albuminuria ( $-2.1$  mL/min/ $1.73$  m<sup>2</sup> per year and  $-4.8$  mL/min/ $1.73$  m<sup>2</sup> per year, respectively). Nonetheless, finerenone slowed chronic eGFR decline compared with placebo in both subgroups (difference in least-squares means


$0.70$ ; 95% CI:  $0.14$ – $1.26$ ;  $P = .01$  and  $1.54$ ; 95% CI:  $0.60$ – $2.48$ ;  $P = .0008$ , respectively) (Fig. 4A and B). Change in UACR from baseline to month 4 by UACR subgroup showed a consistent reduction with finerenone versus placebo in both albuminuria subgroups (Fig. 4C and D).

**A Change in UACR from baseline**




Number at risk		0	4	12	24	36	48
Finerenone	3686	3548	3406	3026	1889	831	
Placebo	3664	3513	3375	3004	1872	811	


**B Albuminuria regression**




**FIGURE 2:** (A) Change in UACR from baseline and (B) albuminuria regression<sup>a</sup> in the overall population. <sup>a</sup>Albuminuria regression defined as change from severely increased to moderately increased albuminuria, or moderately increased to normal albuminuria, accompanied by a UACR decrease from baseline of  $\geq 30\%$ . SD, standard deviation; UACR, urine albumin-to-creatinine ratio.



**FIGURE 3:** Kidney and CV composite endpoints by albuminuria at baseline. CI, confidence interval; CV, cardiovascular; eGFR, estimated glomerular filtration rate; UACR, urine albumin-to-creatinine ratio.



**FIGURE 4:** Kidney markers by albuminuria at baseline. (A) Chronic eGFR slope by treatment arm (UACR: 30 to <300 mg/g); (B) chronic eGFR slope by treatment arm (UACR ≥300 mg/g); (C) change in UACR at month 4 by treatment arm (UACR: 30 to <300 mg/g); and (D) change in UACR at month 4 by treatment arm (UACR ≥300 mg/g). Chronic slope is the annualized change from month 4 to premature discontinuation (PD) or the end-of-study (EOS) visit.



**FIGURE 5:** Time to progression<sup>a</sup> from moderately to severely increased albuminuria in patients with UACR 30 to <300 mg/g at baseline. <sup>a</sup>Progression was defined as a UACR level of ≥300 mg/g that was accompanied by a ≥30% increase in UACR from baseline.

Time to progression to severely increased albuminuria in patients with moderately increased albuminuria at baseline was prolonged in patients treated with finerenone compared with placebo (HR: 0.59; 95% CI: 0.53–0.66;  $P < .0001$ , Fig. 5). Furthermore, time to albuminuria regression was shorter for

the finerenone group than the placebo group, in both those patients with moderately increased albuminuria at baseline (HR: 2.18; 95% CI: 1.92–2.47;  $P < .0001$ ) and those with severely increased albuminuria at baseline (HR: 1.72; 95% CI: 1.56–1.90;  $P < .0001$ ).



**Table 2. Treatment-emergent AEs by albuminuria at baseline**

Patients with treatment-emergent AEs, <i>n</i> (%)	Moderately increased albuminuria (UACR: 30 to <300 mg/g) (baseline eGFR IQR 42–67 mL/min/1.73 m <sup>2</sup> ) ( <i>n</i> = 3406)		Severely increased albuminuria (UACR ≥300 mg/g) (baseline eGFR IQR 68–92 mL/min/1.73 m <sup>2</sup> ) ( <i>n</i> = 3727)	
	Finerenone ( <i>n</i> = 1724)	Placebo ( <i>n</i> = 1682)	Finerenone ( <i>n</i> = 1850)	Placebo ( <i>n</i> = 1877)
Any AE	1507 (87.4)	1483 (88.2)	1532 (82.8)	1562 (83.2)
Related to study drug	327 (19.0)	241 (14.3)	210 (11.4)	161 (8.6)
Leading to discontinuation	133 (7.7)	104 (6.2)	69 (3.7)	72 (3.8)
Any SAE	607 (35.2)	616 (36.6)	516 (27.9)	571 (30.4)
Related to study drug	23 (1.3)	20 (1.2)	10 (0.5)	7 (0.4)
Leading to discontinuation	48 (2.8)	44 (2.6)	20 (1.1)	30 (1.6)
AE leading to death	46 (2.7)	49 (2.9)	31 (1.7)	48 (2.6)
Any hyperkalemia	234 (13.6)	108 (6.4)	148 (8.0)	83 (4.4)
Related to study drug	142 (8.2)	64 (3.8)	89 (4.8)	48 (2.6)
Leading to hospitalization	14 (0.8)	2 (0.1)	6 (0.3)	0
Leading to permanent discontinuation	32 (1.9)	9 (0.5)	12 (0.6)	4 (0.2)
Leading to death	0	0	0	0
Acute kidney injury	59 (3.4)	70 (4.2)	30 (1.6)	26 (1.4)

AE, adverse event; eGFR, estimated glomerular filtration rate; IQR, interquartile range; SAE, serious adverse event; UACR, urine albumin-to-creatinine ratio.

**Cardiovascular outcomes by urine albumin-to-creatinine ratio at baseline.** The effects of finerenone on the CV composite outcome were consistent regardless of UACR at baseline (moderately increased albuminuria: HR: 0.87; 95% CI: 0.73–1.04; severely increased albuminuria: HR: 0.90; 95% CI: 0.75–1.08;  $P_{\text{interaction}} = .60$ ; Fig. 3). The incidence rate of hospitalization for HF was also consistently lower with finerenone compared with placebo in patients with moderately increased albuminuria (HR: 0.73; 95% CI: 0.52–1.03) and severely increased albuminuria at baseline (HR: 0.72; 95% CI: 0.51–1.02;  $P_{\text{interaction}} = .90$ ).

### Safety

The incidences of any treatment-emergent adverse events (TEAEs) were generally balanced between treatment arms and similar between patients with moderately or severely increased albuminuria at baseline (Table 2). It is important to note for interpretation of the safety outcomes that the eGFR interquartile range in the moderately increased albuminuria group was 42–67 mL/min/1.73 m<sup>2</sup>, compared with 68–92 mL/min/1.73 m<sup>2</sup> in patients with severely increased albuminuria. Consequently, hyperkalemia-related TEAEs were observed more frequently in patients with moderately increased albuminuria at baseline in both treatment arms. Nevertheless, incidence of hyperkalemia was approximately twice as frequent with finerenone than with placebo in both albuminuria subgroups (moderately increased albuminuria, 13.6% and 6.4%; severely increased albuminuria, 8.0% and 4.4%, respectively). Discontinuations due to hyperkalemia were low in all groups (<2.0% across treatment arms and UACR subgroups). Acute kidney injury adverse events were balanced between treatment groups within each albuminuria subgroup.

### DISCUSSION

In the primary analysis of FIGARO-DKD, no significant between-group difference was observed for the first composite

kidney endpoint, including a ≥40% decrease in eGFR from baseline [10]. However, a reduction in risk with finerenone treatment was observed for the kidney composite endpoint including a sustained ≥57% decrease in eGFR. A greater risk reduction in these composite kidney endpoints was observed with finerenone in patients with severely increased albuminuria than in patients with moderately increased albuminuria at baseline. Nevertheless, a reduction in chronic eGFR slope was observed with finerenone compared with placebo in both UACR subgroups, as well as a lower likelihood of albuminuria progression in patients with moderately increased albuminuria, indicating that both subgroups of patients are likely to receive kidney benefits from finerenone in the long term. CV outcomes including hospitalization for heart failure were consistently improved with finerenone irrespective of baseline albuminuria.

The results for the eGFR ≥57% kidney composite endpoint are important because it is an established and widely used surrogate endpoint for kidney failure in studies of CKD; in addition, the eGFR ≥57% kidney composite endpoint has higher specificity with kidney failure than the sustained ≥40% decrease in eGFR from baseline for the evaluation of drugs that lead to an initial and transitory eGFR decline [12, 13]. In a comparable HF analysis from the EMPEROR-Preserved trial of empagliflozin in patients with heart failure and preserved ejection fraction, eGFR mean slope change per year was –1.25 and –2.62 mL/min/1.73 m<sup>2</sup> with empagliflozin and placebo, respectively (difference 1.36; 95% CI: 1.06–0.66;  $P < .001$ ). However, the incidence rate of the composite kidney outcome (including a sustained ≥40% decrease in eGFR) was similar between treatment arms (3.6% and 3.7% of patients treated with empagliflozin and placebo, respectively; HR: 0.95; 95% CI: 0.73–1.24) [14]. Reduction in ESKD is a particularly clinically meaningful outcome because of the considerable associated mortality and morbidity as well as the negative impact of ESKD on patients' quality of life and the healthcare cost burdens associated with its management [15–17]. Analysis of UACR over time showed that finerenone lowered the ratio of UACR

from baseline by 32% versus placebo at month 4, an effect that persisted throughout the trial and translated into a shortened time to albuminuria regression with finerenone.

In patients with CKD and T2D, the effect of finerenone on kidney outcomes appeared to be more pronounced for severely increased albuminuria than for moderately increased albuminuria at baseline. Despite this, finerenone slowed the rate of chronic eGFR decline versus placebo in patients in both UACR subgroups; however, because the rate of eGFR decline was slower in patients with moderately increased albuminuria, longer follow-up periods may be required to observe a reduction in risk of kidney failure and sustained eGFR decline outcomes in these patients. In patients with moderately increased albuminuria, finerenone also slowed the rate of albuminuria progression, supporting the idea that finerenone can be expected to improve kidney outcomes over the long term in these patients. Previous research has shown that changes in albuminuria are associated with subsequent risk of outcomes such as ESKD and sustained  $\geq 57\%$  decrease in eGFR across a range of cohorts [4, 18–20]. The kidney benefits finerenone in patients with higher levels of albuminuria may indicate more glomerular inflammation and injury in these patients. Overactivation of the mineralocorticoid receptor and aldosterone upregulation may be contributors to this underlying kidney damage [21], and finerenone is hypothesized to reduce inflammation and fibrosis in the kidney via mineralocorticoid receptor blockade [22]. Preclinical data have demonstrated that finerenone reduces proinflammatory markers and profibrotic markers in the kidney and the heart [23] and prevents kidney glomerular and tubular damage [24]. The treatment benefit with finerenone on the eGFR  $\geq 57\%$  kidney composite endpoint being independent of baseline glycemic control or blood pressure might also suggest a complementary mechanism to SGLT-2is and RAS inhibitors, which are recommended for patients with T2D and CKD, and act primarily via glycemic and/or hemodynamic mechanisms [25, 26].

Finerenone had a similar magnitude of effect on CV outcomes in patients with moderately and severely increased albuminuria at baseline; these included hospitalization for HF, which was the main driver of the finerenone benefit for the CV composite primary endpoint in the FIGARO-DKD primary analysis. These findings highlight the CV benefits in patients with both early- and late-stage CKD and support the need for albuminuria screening in patients with T2D to identify patients with CKD at earlier stages to reduce their CV risk.

Treatment-emergent adverse events were generally well balanced between patients in the finerenone and placebo treatment arms. The incidences of TEAEs leading to discontinuation of the study and serious TEAEs were higher in patients with moderately increased albuminuria compared with patients with severely increased albuminuria at baseline, likely reflective of the lower mean eGFR of the former subgroup. Although total hyperkalemia events were increased with finerenone versus placebo, the incidence of clinically meaningful events was low in both treatment arms, with few hospitalizations or study drug discontinuations due to hyperkalemia, and no hyperkalemia-related deaths.

More hyperkalemia-related TEAEs occurred with moderately increased than severely increased albuminuria; however, this observation is consistent with expectations because decreasing eGFR is an established risk factor for hyperkalemia [27]. In addition to the fact that only short-term data on UACR are available with steroidal MRAs, unlike the long-term follow-up in FIGARO-DKD [28, 29], finerenone also appears to have good tolerability in comparison with the steroidal MRAs based on their respective hyperkalemia profiles. In the phase II ARTS-HF study, finerenone treatment led to less hyperkalemia than spironolactone over 4 weeks in patients with chronic HF with reduced ejection fraction and moderate CKD [30]. Finerenone also does not appear to be associated with any sexual side effects, unlike spironolactone [22].

With this analysis, special consideration had to be given for the inclusion criteria of FIGARO-DKD, which meant that patients with moderately increased albuminuria had lower eGFR values than those patients with severely increased albuminuria (Supplementary data, Fig. S1) [10]. Although most analyses were prespecified, confirmatory testing was only applied to the CV and eGFR  $\geq 40\%$  kidney composite endpoints, due to the hierarchical testing strategy, which stopped at the first nonsignificant result. Therefore, the analyses described here are mostly exploratory and hypothesis-generating in nature.

Overall, the results of this analysis suggest that finerenone offers an important advance in treatment for patients with CKD and T2D with either moderately or severely increased albuminuria to protect against kidney disease progression and CV events. The findings also emphasize the need for albuminuria screening in patients with T2D because early initiation of treatment can reduce the risk of CV events and progression of albuminuria in patients with moderately increased albuminuria.

## SUPPLEMENTARY DATA

Supplementary data are available at *ndt* online.

## ACKNOWLEDGEMENTS

We are indebted to the patients who have participated in this trial, the FIGARO-DKD trial investigators, and the study centers that supported the trial. The FIGARO-DKD study and subanalyses were funded by Bayer AG. Medical writing assistance was provided by Emilie Topley, on behalf of Chameleon Communications International, and was funded by Bayer AG. This work was supported by Bayer AG, who funded the FIGARO-DKD study and the reported analysis.

## AUTHORS' CONTRIBUTIONS

The Executive Committee designed the study in conjunction with the sponsor. Luis Ruilope and George Bakris wrote the first draft of the report. All authors were involved in data analysis and interpretation, and in drafting and critically revising the report. All authors had access to study results and the first and corresponding author assume responsibility for the integrity and accuracy of the data reported. All authors

reviewed and approved the final submitted version of the report.

## CONFLICT OF INTEREST STATEMENT

L.M.R. reported receipt of consultancy fees from Bayer. B.P. reported consultant fees for AstraZeneca, Bayer, Boehringer Ingelheim, Brainstorm Medical, Cereno Scientific, G3 Pharmaceuticals, KBP Biosciences, PhaseBio, Proton Intel, Sanofi/Lexicon, Sarfez, scPharmaceuticals, SQ Innovation, Tricida and Vifor/Relypsa; he has stock options for KBP Biosciences, Brainstorm Medical, Cereno Scientific, G3 Pharmaceuticals, Proton Intel, Sarfez, scPharmaceuticals, SQ Innovation, Tricida, Vifor/Relypsa; he also holds a patent for site-specific delivery of eplerenone to the myocardium (US patent #9 931 412) and a provisional patent for histone-acetylation-modulating agents for the treatment and prevention of organ injury (provisional patent US 63/045 784). S.D.A. has received research support from Abbott Vascular and Vifor International, and personal fees from Abbott Vascular, Bayer, Boehringer Ingelheim, BRAHMS, Cardiac Dimensions, Impulse Dynamics, Novartis, Servier and Vifor Pharma. P.R. reported personal fees from Bayer during the conduct of the study; he has received research support and personal fees from AstraZeneca and Novo Nordisk, and personal fees from Astellas, Boehringer Ingelheim, Eli Lilly, Gilead, Mundipharma, Sanofi and Vifor; all fees are given to Steno Diabetes Center Copenhagen. C.P.K. reported that he is a consultant for Abbott, Akebia, AstraZeneca, Bayer, Boehringer Ingelheim, Cara Therapeutics, CSL Behring, GSK, Rockwell and Vifor. R.P.-F. reported honoraria fees from Akebia, AstraZeneca, Bayer and Boehringer Ingelheim, and investigator-initiated trial support from Fresenius Medical Care. P.P. reported that he is a consultant for Bayer. A.J., A.L. and N.M. are full-time employees of Bayer AG, Germany. M.F.S. is a full-time employee of Bayer AG, Germany. He is also a shareholder in AstraZeneca, Bayer, Eli Lilly and Novo Nordisk. G.L.B. reported research funding, paid to the University of Chicago Medicine, from Bayer during the conduct of the study; he also reported research funding, paid to the University of Chicago Medicine, from Novo Nordisk and Vascular Dynamics; he acted as a consultant and received personal fees from for Alnylam, Merck and Relypsa; he is an editor of the *American Journal of Nephrology*, *Nephrology* and *Hypertension*, and section editor of *UpToDate*; and is an associate editor of *Diabetes Care* and *Hypertension Research*.

## FUNDING

This work was supported by Bayer AG, who funded the FIGARO-DKD study and the reported analysis.

## REFERENCES

1. United States Renal Data System. 2018 USRDS Annual Data Report Volume 2: ESRD in the United States. Chapter 1: Incidence, prevalence, patient characteristics, and treatment modalities. Minneapolis, United States: USRDS Coordinating Center. 2018; [https://usrds.org/media/1736/v2\\_c01\\_increv\\_18\\_usrds.pdf](https://usrds.org/media/1736/v2_c01_increv_18_usrds.pdf) (6 October 2021, date last accessed)

2. Wu B, Bell K, Stanford A *et al*. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012. *BMJ Open Diabetes Res Care* 2016; 4: e000154
3. Afkarian M, Sachs MC, Kestenbaum B *et al*. Kidney disease and increased mortality risk in type 2 diabetes. *J Am Soc Nephrol* 2013; 24: 302–308
4. Fox CS, Matsushita K, Woodward M *et al*. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. *Lancet* 2012; 380: 1662–1673
5. American Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes–2020. *Diabetes Care* 2020; 43: S135–S151
6. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. *Kidney Int* 2020; 98: S1–S115
7. Perkovic V, Jardine MJ, Neal B *et al*. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med* 2019; 380: 2295–2306
8. Oshima M, Neuen BL, Li J *et al*. Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post hoc analysis from the CREDENCE trial. *J Am Soc Nephrol* 2020; 31: 2925–2936
9. Bakris GL, Agarwal R, Anker SD *et al*. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med* 2020; 383: 2219–2229
10. Pitt B, Filippatos G, Agarwal R *et al*. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. *N Engl J Med* 2021; 385: 2252–2263
11. Ruilope LM, Agarwal R, Anker SD *et al*. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. *Am J Nephrol* 2019; 50: 345–356
12. Levey AS, Inker LA, Matsushita K *et al*. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the national kidney foundation and the US food and drug administration. *Am J Kidney Dis* 2014; 64: 821–835
13. Levey AS, Gansevoort RT, Coresh J *et al*. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the national kidney foundation in collaboration with the US food and drug administration and European medicines agency. *Am J Kidney Dis* 2020; 75: 84–104
14. Anker SD, Butler J, Filippatos G *et al*. Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med* 2021; 385: 1451–1461
15. Eriksson JK, Neovius M, Jacobson SH *et al*. Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden. *BMJ Open* 2016; 6: e012062
16. Elshahat S, Cockwell P, Maxwell AP *et al*. The impact of chronic kidney disease on developed countries from a health economics perspective: a systematic scoping review. *PLoS One* 2020; 15: e0230512
17. Kefale B, Alebachew M, Tadesse Y *et al*. Quality of life and its predictors among patients with chronic kidney disease: a hospital-based cross sectional study. *PLoS One* 2019; 14: e0212184
18. Coresh J, Heerspink HJL, Sang Y *et al*. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. *Lancet Diabetes Endocrinol* 2019; 7: 115–127
19. Heerspink HJL, Greene T, Tighiouart H *et al*. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. *Lancet Diabetes Endocrinol* 2019; 7: 128–139
20. Sumida K, Molnar MZ, Potukuchi PK *et al*. Changes in albuminuria and subsequent risk of incident kidney disease. *Clin J Am Soc Nephrol* 2017; 12: 1941–1949
21. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. *Hypertension* 2015; 65: 257–263
22. Agarwal R, Kolkhof P, Bakris G *et al*. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. *Eur Heart J* 2021; 42: 152–161
23. Kolkhof P, Delbeck M, Kretschmer A *et al*. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. *J Cardiovasc Pharmacol* 2014; 64: 69–78
24. Barrera-Chimal J, Andre-Gregoire G, Nguyen Dinh Cat A *et al*. Benefit of mineralocorticoid receptor antagonism in AKI: role of vascular smooth muscle rac1. *J Am Soc Nephrol* 2017; 28: 1216–1226

25. Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. *J Am Coll Cardiol* 2018; 72: 1845–1855
26. Jafar TH, Schmid CH, Landa M *et al.* Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. *Ann Intern Med* 2001; 135: 73–87
27. Kovesdy CP, Matsushita K, Sang Y *et al.* Serum potassium and adverse outcomes across the range of kidney function: a CKD prognosis consortium meta-analysis. *Eur Heart J* 2018; 39: 1535–1542
28. Epstein M, Williams GH, Weinberger M *et al.* Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. *Clin J Am Soc Nephrol* 2006; 1: 940–951
29. Davidson MB, Wong A, Hamrahian AH *et al.* Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors. *Endocr Pract* 2008; 14: 985–992
30. Pitt B, Kober L, Ponikowski P *et al.* Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. *Eur Heart J* 2013; 34: 2453–2463

Received: 20.10.2021; Editorial decision: 18.2.2022